The short answer: medical weight loss at our Williamsburg, VA practice is a clinical program. Bloodwork, screening, a prescription where it is appropriate, and monthly follow-up. The medication does real work. Nutrition, protein and strength training are what turn that into a result you keep.
People come to us about weight after they have already done a lot. They have tried plans, tracked food, and pushed through workouts. Something is still in the way. That is usually where we come in.
Why isn't willpower the whole story?
Because appetite, satiety and energy storage are biology, and the guidance treats them that way.
The US Preventive Services Task Force recommends that clinicians offer or refer adults with a BMI of 30 or higher to intensive, multicomponent behavioural programs, and grades that recommendation B (USPSTF). Across the pooled trials, participants in those programs were about twice as likely to reach a 5% weight loss as controls, and the incidence of type 2 diabetes fell by roughly a third.
That is what a structured program adds on its own, before any medication enters the picture.
Where do hormones and metabolism fit?
Insulin, cortisol, thyroid and the sex hormones all influence how your body holds and burns energy, and sleep and stress sit on top of them. If several are off-step, which is common from the late thirties onward, the scale gets sticky even without changes to how you eat.
We often start a weight conversation by also having a hormone conversation, because we run both sides of that here and addressing one without the other leaves work on the table.
Which medications are approved for weight?
Worth getting right, because the brand names get used interchangeably and they are not interchangeable.
| Brand | Molecule | Approved for weight management |
|---|---|---|
| Wegovy | Semaglutide | Yes |
| Zepbound | Tirzepatide | Yes |
| Ozempic | Semaglutide | No, approved for type 2 diabetes |
| Mounjaro | Tirzepatide | No, approved for type 2 diabetes |
Semaglutide is a GLP-1 receptor agonist. Tirzepatide acts on GLP-1 and also on GIP, a second gut hormone pathway. Both slow gastric emptying and signal fullness sooner, which is why people describe food occupying less of their attention rather than forced restriction.
Prescribing Ozempic or Mounjaro for weight is off-label. That is lawful and sometimes reasonable, and we will tell you plainly which you are being prescribed and why. Our full comparison of semaglutide and tirzepatide covers the differences.
What does a program with us include?
- A real consult and screening, so we know this is the right path before anything is prescribed.
- Bloodwork and a clinical baseline.
- Personalised dosing, titrated slowly, because starting low and going gradually is how the first weeks stay comfortable.
- Monthly check-ins for progress, tolerance and adjustment.
- Nutrition guidance, with protein and resistance training built in from week one.
- Body composition tracking, so we know what you are actually losing.
That last pair is not just our preference. The American Diabetes Association's 2026 standards of care carry a Level A recommendation that nutrition, physical activity and behavioural therapy be used in combination with obesity medications, and advise resistance training to preserve lean mass alongside a protein target commonly set at 1.2 to 1.6 grams per kilogram per day (ADA, BMJ Open Diabetes Research and Care). They suggest reassessing every three months, which is close to our own rhythm.
What does the first year look like?
The first month is mostly about settling in at a low dose. Most people get some gastrointestinal effects early, usually nausea, and they typically ease as your body adjusts. Slowing the dose increase is the standard fix, and it is a conversation rather than a setback.
From there, progress is steady rather than dramatic. The pivotal trials ran over 68 to 72 weeks, which is the honest timeframe to plan around.
Will you lose muscle?
Some of what you lose is lean tissue, in roughly the proportion seen with any diet-driven weight loss (Rossi et al., Acta Diabetologica).
That is exactly why protein and resistance training are in the program rather than bolted on at the end. A meta-analysis of 114 randomized trials found lean mass was maintained in interventions that included resistance training, and that finding is why the ADA recommends it alongside medication. Body composition testing tells us whether the plan is working, which scale weight alone cannot.
Is this a long-term treatment?
Yes, and it is more useful to know that at the start.
Obesity is managed the way other chronic conditions are managed, and the trial data supports staying with it. In SURMOUNT-4, participants who had lost 20.9% over 36 weeks and continued treatment went on to reach 26.0% total mean weight loss by week 88 (Aronne et al., JAMA). Continuing is what compounds the result.
That is why we talk about the long view from your first appointment: when to titrate, when to hold, and what maintenance looks like. It is also why the habits matter, because they are the part that stays with you regardless.
The goal is not the lowest weight you can hit. It is the healthiest body composition you can hold.
What we'll talk about at your consult
- Your history, previous attempts, and what got in the way.
- Personal and family history, including any history of medullary thyroid carcinoma or MEN 2 syndrome, which rules out this class of medication.
- Whether you are pregnant or planning to be, since these medications are stopped in pregnancy and at least two months before trying.
- Current medications, including any other GLP-1, which is not combined with these.
- Gallbladder and pancreatic history, and how we will monitor.
- What success looks like for you beyond a number.
Both medications carry a boxed warning relating to thyroid C-cell tumors seen in rodents, and we go through that with you rather than leaving it in a leaflet.
What about coverage?
The landscape improved this year. Medicare launched a GLP-1 Bridge program on July 1, 2026, covering Wegovy, Zepbound in the KwikPen presentation, and Foundayo for qualifying Part D enrollees at a $50 copay per monthly supply, running through the end of 2027 (Medicare.gov). Eligibility runs by BMI and condition.
Commercial coverage varies widely, so checking your own plan is worth the phone call, and we can tell you what to ask.
Targeted support like wellness injections or an occasional IV drip can help with hydration and nutritional support while intake is reduced. Neither is a weight-loss treatment, and we do not sell them as one.
Book a consultation and we'll look at your history and labs together and build the plan either way.
